Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

This randomized phase II trial tested nanoparticle albumin-bound paclitaxel (nab-P) in 3 different schedules: weekly, every 2 weeks (q2W), and every 3 weeks (q3W). Because bevacizumab prolonged progression-free survival in earlier trials with taxanes in metastatic breast cancer (MBC), all the patients received this agent. Weekly nanoparticle albumin-bound paclitaxel (nab-P) appeared to have the highest therapeutic index, but treatment was limited by sensory neuropathy.